MARKET

PRTA

PRTA

Prothena
NASDAQ
60.63
+1.16
+1.95%
After Hours: 60.55 -0.08 -0.13% 19:51 09/30 EDT
OPEN
59.00
PREV CLOSE
59.47
HIGH
64.00
LOW
58.83
VOLUME
1.78M
TURNOVER
0
52 WEEK HIGH
74.32
52 WEEK LOW
21.06
MARKET CAP
2.84B
P/E (TTM)
-256.9068
1D
5D
1M
3M
1Y
5Y
Biogen, Eisai cool off after massive run-up following lecanemab Alzheimer's data
The juggernaut rise in the stock prices of Biogen (NASDAQ:BIIB) and E...
Seekingalpha · 2d ago
Oppenheimer Maintains Outperform on Prothena Corp, Raises Price Target to $110
Oppenheimer analyst Jay Olson maintains Prothena Corp (NASDAQ:PRTA) with a Outperform and raises the price target from $100 to $110.
Benzinga · 3d ago
Oppenheimer Adjusts Prothena Price Target to $110 From $100, Maintains Outperform Rating
Oppenheimer Adjusts Prothena Price Target to $110 From $100, Maintains Outperform Rating
MT Newswires · 3d ago
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.
Benzinga · 3d ago
Netflix, Biogen And Other Big Gainers From Wednesday
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.
Benzinga · 3d ago
Many Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai data
Biogen (NASDAQ:BIIB) and Eisai (<a href="https://seekingalpha.com/symbol/ES...
Seekingalpha · 3d ago
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Benzinga · 3d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers
Benzinga · 3d ago
More
About PRTA
Prothena Corporation plc is a late-stage clinical company engaged in the protein dysregulation and a pipeline of novel investigational therapies for rare peripheral amyloid and neurodegenerative diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and novel targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company is also advancing several discovery and preclinical-stage programs for neurological diseases with significant unmet medical needs such as AD and amyotrophic lateral sclerosis (ALS). The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis. The Company's pipeline includes AL Amyloidosis & Birtamimab, Parkinson’s Disease & Prasinezumab, Transthyretin amyloidosis (ATTR) & PRX004, Alzheimer’s Disease and Pioneering Neuroscience.

Webull offers kinds of Prothena Corporation PLC stock information, including NASDAQ:PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.